GlassScriptPhysician profile
Blair Wagoner
NPI 1366220907
$3,306.11
in general payments reported to CMS, 2019-2025
19 companies · $786 in 2025
The $786 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $302 · 2024: $2,218 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,294 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.96 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $646.15 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $529.05 | 2023-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $490.79 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $331.89 | 2023-2025 | Caplyta |
| Alkermes, INC. | $236.93 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $227.74 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $157.78 | 2024-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $99.79 | 2023-2024 | Spravato, Invega Sustenna |
| Lundbeck LLC | $98.33 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $94.32 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $89.70 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $63.78 | 2024 | |
| Tris Pharma INC | $56.30 | 2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $47.34 | 2024 | Qelbree |
| Axsome Therapeutics, INC. | $40.18 | 2024 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $32.80 | 2025 | Jornay Pm |
| Indivior INC. | $31.51 | 2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $17.80 | 2025 | Trintellix |
| Neos Therapeutics, LP | $13.93 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blair Wagoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.